Compare AUBN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | ACRV |
|---|---|---|
| Founded | 1907 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 74.0M |
| IPO Year | 1996 | 2022 |
| Metric | AUBN | ACRV |
|---|---|---|
| Price | $26.86 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 1.9K | ★ 216.5K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | 13.66 | ★ 15.13 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.51 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.01 | $1.27 |
| 52 Week High | $28.88 | $3.56 |
| Indicator | AUBN | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 40.97 |
| Support Level | $26.02 | $1.63 |
| Resistance Level | $27.64 | $2.21 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 53.04 | 20.45 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.